[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.", "fullTimeEmployees": 74, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 53, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 65, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 905293, "exercisedValue": 0, "unexercisedValue": 219686}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Dr. Martin Douglas Auster M.D.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.22, "open": 2.18, "dayLow": 2.07, "dayHigh": 2.21, "regularMarketPreviousClose": 2.22, "regularMarketOpen": 2.18, "regularMarketDayLow": 2.07, "regularMarketDayHigh": 2.21, "beta": 0.385, "forwardPE": -0.9519651, "volume": 554036, "regularMarketVolume": 554036, "averageVolume": 1099345, "averageVolume10days": 1217040, "averageDailyVolume10Day": 1217040, "bid": 2.16, "ask": 2.19, "bidSize": 300, "askSize": 400, "marketCap": 153688464, "fiftyTwoWeekLow": 1.865, "fiftyTwoWeekHigh": 38.2, "fiftyDayAverage": 3.7957, "twoHundredDayAverage": 7.3199, "currency": "USD", "enterpriseValue": -137410992, "floatShares": 51660850, "sharesOutstanding": 70499296, "sharesShort": 7948658, "sharesShortPriorMonth": 8306506, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.11270001, "heldPercentInsiders": 0.03178, "heldPercentInstitutions": 0.94429, "shortRatio": 6.51, "shortPercentOfFloat": 0.1321, "bookValue": 4.355, "priceToBook": 0.50057405, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -192603008, "trailingEps": -3.24, "forwardEps": -2.29, "enterpriseToEbitda": 0.664, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VTYX", "underlyingSymbol": "VTYX", "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "firstTradeDateEpochUtc": 1634823000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f523c464-d79a-3f62-beea-fdbd09f3b782", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.18, "targetHighPrice": 21.0, "targetLowPrice": 5.0, "targetMeanPrice": 10.8, "targetMedianPrice": 9.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 302582016, "totalCashPerShare": 4.292, "ebitda": -207012992, "totalDebt": 11494000, "quickRatio": 20.819, "currentRatio": 22.001, "debtToEquity": 3.744, "returnOnAssets": -0.35911998, "returnOnEquity": -0.56764, "freeCashflow": -109898248, "operatingCashflow": -183226000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]